Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial

@inproceedings{Marina2016ComparisonOM,
  title={Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial},
  author={Neyssa M Marina and Sigbj\orn S Smeland and Stefan S. Bielack and Mark L. Bernstein and Gordana Jovic and Mark D. Krailo and Jane M. Hook and Carola A. S. Arndt and Hendrik P van den Berg and Bernadette Brennan and B{\'e}n{\'e}dicte Brichard and Ken L B Brown and Trude Butterfass-Bahloul and Gabriele Calaminus and Heike E. Daldrup-Link and Mikael Eriksson and Mark C. Gebhardt and Hans Gelderblom and Joachim Ger\ss and Robert E Goldsby and Allen M Goorin and Richard Greg Gorlick and Holcombe E. Grier and Juliet P. Hale and Kirsten Sundby Hall and Jendrik Hardes and Douglas S Hawkins and Knut Helmke and P. C. W. Hogendoorn and Michael S Isakoff and Katherine A Janeway and Heribert J{\"u}rgens and Leo Kager and Thomas K{\"u}hne and Ching C. Lau and Patrick S Leavey and Stephen L Lessnick and Leo Mascarenhas and Paul A. Meyers and Hubert Mottl and Michaela Nathrath and Zsuzsanna P{\'a}pai and Robert Lor Randall and Peter Reichardt and Marleen M Renard and Akmal Safwat and Cindy L. Schwartz and Michael C. G. Stevens and Sandra J. Strauss and Lisa A. Teot and Mathias Werner and Matthew R. Sydes and Jeremy Simon Whelan},
  booktitle={The Lancet. Oncology},
  year={2016}
}
BACKGROUND We designed the EURAMOS-1 trial to investigate whether intensified postoperative chemotherapy for patients whose tumour showed a poor response to preoperative chemotherapy (≥10% viable tumour) improved event-free survival in patients with high-grade osteosarcoma. METHODS EURAMOS-1 was an open-label, international, phase 3 randomised, controlled trial. Consenting patients with newly diagnosed, resectable, high-grade osteosarcoma aged 40 years or younger were eligible for… CONTINUE READING